Cost of treatment of metastatic non-small lung cancer in Sweden, 2011–2023
DOI:
https://doi.org/10.2340/1651-226X.2025.44650Keywords:
Metastatic non-small cell lung cancer, Immune-oncology, EGFR-targeted therapy, ALK-targeted therapy, Healthcare resource use, cancer costAbstract
Background and purpose: Metastatic non-small cell lung cancer (mNSCLC) contributes to the economic burden. Over the past decade, treatment has evolved with the introduction of epidermal growth factor receptor (EGFR) anaplastic lymphoma kinase (ALK)-targeted, and immune-oncology (IO) drugs. However, limited evidence exists on the long-term costs of mNSCLC treatments in Sweden.
Patient/material and methods: This population-based retrospective study used data from the National Board of Health and Welfare, identifying patients initially diagnosed with stage IV NSCLC between 2011 and 2020. Healthcare costs, including inpatient care, outpatient care, and drug expenses, were assessed using Diagnosis-Related Group (DRG) tariffs and prescription data. Drug expenses exceeding DRG tariff limits, such as IO drugs, were calculated separately based on retail list prices. Costs were analyzed over 5 years post-diagnosis and adjusted to 2023 values.
Results: A total of 17,107 patients were included. IO drug use increased sharply after 2016, becoming the predominant therapy. EGFR- and ALK-targeted drug use steadily increased. Overall costs rose over time, especially in the first year after diagnosis. The first-year mean cost was highest among patients receiving IO drugs (€105,286), primarily due to drug acquisition, but declined in subsequent years. ALK- and EGFR-targeted therapies also had high initial costs but remained stable thereafter.
Interpretation: This study highlights the increasing economic burden of mNSCLC treatment in Sweden, driven by the targeted and IO drugs. While ALK-, EGFR-targeted, and IO drugs contribute to high first-year mean costs, IO drug costs decline significantly in subsequent years after diagnosis.
Downloads
References
Socialstyrelsen. Statistical database, cancer [Internet]. 2024. [accessed in September, 2024] Available from: https://www.socialstyrelsen.se
Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165–74.
https://doi.org/10.1016/S1470-2045(13)70442-X DOI: https://doi.org/10.1016/S1470-2045(13)70442-X
Cancer Research UK. Lung cancer UK price tag eclipses the cost of any other cancer. 2012, Cancer Research UK, London.
Hofmarcher T, Lindgren P, Wilking N, Jönsson B. The cost of cancer in Europe 2018. Eur J Cancer. 2020;129:41–9.
https://doi.org/10.1016/j.ejca.2020.01.011 DOI: https://doi.org/10.1016/j.ejca.2020.01.011
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
https://doi.org/10.1056/NEJMoa0810699 DOI: https://doi.org/10.1056/NEJMoa0810699
Bollinger MK, Agnew AS, Mascara GP. Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract. 2018;24(5):379–88.
https://doi.org/10.1177/1078155217712401 DOI: https://doi.org/10.1177/1078155217712401
Rothschild SI, Gautschi O. Crizotinib in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2013;14(5):473–80.
https://doi.org/10.1016/j.cllc.2013.04.006 DOI: https://doi.org/10.1016/j.cllc.2013.04.006
Ryser CO, Diebold J, Gautschi O. Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives. Curr Opin Oncol. 2019;31(1):8–12.
https://doi.org/10.1097/CCO.0000000000000494 DOI: https://doi.org/10.1097/CCO.0000000000000494
Midha A, Dearden SMc, Cormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911.
Addeo A, Tabbò F, Robinson T, Buffoni L, Novello S. Precision medicine in ALK rearranged NSCLC: a rapidly evolving scenario. Crit Rev Oncol Hematol. 2018;122:150–6.
https://doi.org/10.1016/j.critrevonc.2017.12.015 DOI: https://doi.org/10.1016/j.critrevonc.2017.12.015
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.
https://doi.org/10.1056/NEJMoa1504627 DOI: https://doi.org/10.1056/NEJMoa1504627
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
https://doi.org/10.1056/NEJMoa1606774 DOI: https://doi.org/10.1056/NEJMoa1606774
García-González J, Ruiz-Bañobre J, Afonso-Afonso FJ, Amenedo-Gancedo M, Areses-Manrique MDC, Campos-Balea B, et al. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: a pairwise meta-analysis. J Clin Med. 2020;9(7):2093.
https://doi.org/10.3390/jcm9072093 DOI: https://doi.org/10.3390/jcm9072093
The Dental and Pharmaceutical Benefits Agency, TLV_3331_2016: Underlag för beslut i landstingen – Keytruda (pembrolizumab), Keytruda som monoterapi är indicerat som första linjens behandling av metastaserad icke-småcellig lungcancer (NSCLC) hos vuxna vars tumörer uttrycker PD-L1 i ≥ 50 % av tumörcellerna (tumour proportion score (TPS) ≥ 50 %) och som inte är positiva för mutationer i EGFR eller ALK. Tandvårds- och läkemedelsförmånsverket (TLV); 2017, Stockholm.
The Dental and Pharmaceutical Benefits Agency, TLV_875_2016: Underlag för beslut i landstingen – Opdivo (nivolumab) för behandling av vuxna med lokalt avancerad eller metastaserande icke-småcellig lungcancer (NSCLC) av icke-skivepiteltyp efter tidigare kemoterapi. Tandvårds- och läkemedelsförmånsverket (TLV); 2016, Stockholm.
The Dental and Pharmaceutical Benefits Agency, TLV_1166_2016: Underlag för beslut i landstingen – Keytruda (pembrolizumab) för behandling av lokalt avancerad eller metastaserad PD L1-positiv icke-småcellig lungcancer (NSCLC) hos vuxna som tidigare behandlats med åtminstone en kemoterapiregim. Tandvårds- och läkemedelsförmånsverket (TLV); 2016, Stockholm.
The Dental and Pharmaceutical Benefits Agency, TLV_2395_2016: Underlag för beslut i landstingen – Tecentriq (atezolizumab) för behandling av vuxna patienter med lokalt avancerad eller metastaserad icke-småcellig lungcancer (NSCLC) efter tidigare behandling med kemoterapi. Tandvårds- och läkemedelsförmånsverket (TLV); 2018, Stockholm.
The Dental and Pharmaceutical Benefits Agency, TLV_2440_2019: Underlag för beslut i landstingen – Tecentriq (atezolizumab) i kombination med karboplatin och etoposid är indicerat för första linjens behand ling av vuxna patienter med utbredd småcellig lungcancer (ES-SCLC). Tandvårds- och läkemedelsförmånsverket (TLV); 2019, Stockholm.
The Dental and Pharmaceutical Benefits Agency, TLV_4226_2014: Underlag för beslut i landstingen – Opdivo (nivolumab) för att behandla vuxna patienter med en avancerad form av lungcancer som spridit sig eller vuxit trots tidigare behandling med kemoterapi. Tandvårds- och läkemedelsförmånsverket (TLV); 2015, Stockholm.
Gouliaev A, Rasmussen TR, Malila N, Fjellbirkeland L, Löfling L, Jakobsen E, et al. Lung cancer registries in Denmark, Finland, Norway and Sweden: a comparison and proposal for harmonization. Acta Oncol. 2023;62(1):1–7.
https://doi.org/10.1080/0284186X.2023.2172687 DOI: https://doi.org/10.1080/0284186X.2023.2172687
Socialstyrelsen. Viktlistor för NordDRG [Interenet]. [accessed in Setember, 2024] Available from: https://www.socialstyrelsen.se/statistik-och-data/klassifikationer-och-koder/drg/viktlistor/.
Busse R, Geissler A, Aaviksoo A, Cots F, Häkkinen U, Kobel C, et al. Diagnosis related groups in Europe: moving towards transparency, efficiency, and quality in hospitals? BMJ. 2013;346:f3197.
https://doi.org/10.1136/bmj.f3197 DOI: https://doi.org/10.1136/bmj.f3197
Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The Phase III POSEIDON study. J Clin Oncol. 2023;41(6):1213–27.
https://doi.org/10.1200/JCO.22.00975 DOI: https://doi.org/10.1200/JCO.22.00975
Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, et al. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1–positive, advanced non–small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol. 2020;38(14):1580–90.
https://doi.org/10.1200/JCO.19.02446 DOI: https://doi.org/10.1200/JCO.19.02446
European Medicines Agency, Summary of Product Characteristics. Opdivo in combination with ipilimumab in non-small cell lung cancer. European Medicines Agency, Amsterdam.
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv192–237.
https://doi.org/10.1093/annonc/mdy275 DOI: https://doi.org/10.1093/annonc/mdy275
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆. Ann Oncol. 2023;34(4):339–57.
https://doi.org/10.1016/j.annonc.2022.12.009 DOI: https://doi.org/10.1016/j.annonc.2022.12.009
Official Statistics of Sweden. Consumer Price Index (CPI) [Internet]. [accessed in September, 2024] Available from: https://www.scb.se
European Central Bank, ECB statistics, Swedish Krona (SEK). Average from 2 January 2023 to 29 December 2023 [Internet]. [accessed in September, 2024] Available from: https://www.ecb.europa.eu
Li FDong X. Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: the 5-year outcomes of the KEYNOTE-024 trial. Thorac Cancer. 2021;12(23):3085–7.
https://doi.org/10.1111/1759-7714.14193 DOI: https://doi.org/10.1111/1759-7714.14193
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92.
https://doi.org/10.1056/NEJMoa1801005 DOI: https://doi.org/10.1056/NEJMoa1801005
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51.
https://doi.org/10.1056/NEJMoa1810865 DOI: https://doi.org/10.1056/NEJMoa1810865
Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):Jco2001605.
https://doi.org/10.1200/JCO.20.01605 DOI: https://doi.org/10.1200/JCO.20.01605
Brahmer JR, Lee J-S, Ciuleanu T-E, Caro RB, Nishio M, Urban L, et al., Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): results from CheckMate 227. 2022;40(17_suppl):LBA9025.
https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA9025 DOI: https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA9025
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al., Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.
https://doi.org/10.1056/NEJMoa1913662 DOI: https://doi.org/10.1056/NEJMoa1913662
Planchard D, Jänne PA, Cheng Y, Yang JC-H, Yanagitani N, Kim S-W, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935–48.
https://doi.org/10.1056/NEJMoa2306434 DOI: https://doi.org/10.1056/NEJMoa2306434
Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al., Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056–64.
https://doi.org/10.1016/j.annonc.2020.04.478 DOI: https://doi.org/10.1016/j.annonc.2020.04.478
Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, et al., Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the Phase III CROWN study. J Clin Oncol. 2024;42(29):3400–9.
https://doi.org/10.1200/JCO.24.00581 DOI: https://doi.org/10.1200/JCO.24.00581
Leskelä RL, Korhonen S, Haavisto I, Nuutinen M, Peltonen E, Herse F, et al., Trends in cost of treatment of lung cancer patients in 2014–2019 in Finland – a descriptive register study. Acta Oncol. 2023;62(6):587–93.
https://doi.org/10.1080/0284186X.2023.2218040 DOI: https://doi.org/10.1080/0284186X.2023.2218040
Manzano A, Svedman C, Hofmarcher T, Wilking N. Comparator report on cancer in Europe 2025 – disease burden, costs and access to medicines and molecular diagnostics [Internet]. Available from: https://ihe.se/en/rapport
Gouliaev A, Risikesan J, Christensen NL, Rasmussen TR, Hilberg O, Ibsen R, et al. Direct and indirect economic burden of lung cancer in Denmark a nationwide study. Eur Clin Respir J. 2021;8(1):1951963.
https://doi.org/10.1080/20018525.2021.1951963 DOI: https://doi.org/10.1080/20018525.2021.1951963
Bugge C, Sæther EM, Brustugun OT, Kristiansen IS. Societal cost of cancer in Norway –results of taking a broader cost perspective. Health Policy. 2021;125(8):1100–7.
https://doi.org/10.1016/j.healthpol.2021.05.008 DOI: https://doi.org/10.1016/j.healthpol.2021.05.008
The Dental and Pharmaceutical Benefits Agency. International price comparison 2023, an analysis of Swedish pharmaceutical prices in relation to 19 other European countries [Internet]. 2023. Available from: https://www.tlv.se
Sveriges Kommuner och Regioner. Regionernas samverkansmodell för läkemedel, Avtal [Internet]. Available from: https://samverkanlakemedel.se
Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. S Med Rev. 2012;5(1):38–46.
https://doi.org/10.2174/1876824501305010001 DOI: https://doi.org/10.2174/1876824501305010001
Bergqvist J, Ljunggren G. The impact of integrated home palliative care services on resource use and place of death. J Palliat Med. 2020;23(1):67–73.
https://doi.org/10.1089/jpm.2018.0639 DOI: https://doi.org/10.1089/jpm.2018.0639
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Kun Kim, Michael Sweeting, Nils Wilking, Linus Mattias Jönsson
This work is licensed under a Creative Commons Attribution 4.0 International License.
